STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
radiology

AbbVie to Acquire Landos Biopharma: Advancing Novel Oral Therapies for Autoimmune Diseases

byLiliana Vida
March 25, 2024
in Biotechnology, Large-Cap, Pharmaceuticals
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

AbbVie’s Acquisition of Landos Marks a Strategic Move in Autoimmune Disease Treatment Development

AbbVie Inc. (ABBV) has announced a definitive agreement to acquire Landos Biopharma, Inc. (LABP), a clinical-stage biopharmaceutical company specializing in the development of oral therapeutics for autoimmune diseases. The acquisition signals AbbVie’s commitment to advancing innovative treatments for conditions like ulcerative colitis (UC) and Crohn’s disease.

Central to this acquisition is Landos’ lead investigational asset, NX-13, a first-in-class, oral NLRX1 agonist with a bimodal mechanism of action. NX-13 shows promise in addressing inflammation and facilitating epithelial repair, offering a novel approach to treating autoimmune diseases.

Roopal Thakkar, M.D., Senior Vice President and Chief Medical Officer of Global Therapeutics at AbbVie, expressed optimism about the potential of NX-13 to impact the lives of patients with UC and Crohn’s disease. The acquisition reflects AbbVie’s dedication to advancing therapies that address unmet medical needs in autoimmune diseases.

Gregory Oakes, President and CEO of Landos, highlighted the significance of this agreement, underscoring the potential of NX-13 to fill therapeutic gaps in the treatment landscape. Landos’ expertise, combined with AbbVie’s leadership in therapeutic areas and global development, positions the companies for significant progress in autoimmune disease treatment.

The proposed transaction, valued at approximately $212.5 million, is subject to customary closing conditions, including approval by Landos’ stockholders, and is expected to close in the second quarter of 2024. As AbbVie moves forward with this acquisition, the collaboration between the two companies holds promise for advancing innovative therapies and improving outcomes for patients with autoimmune diseases.

You might like this article:Disney Stock Surges on Wall Street Upgrade

Previous Post

Disney Stock Surges on Wall Street Upgrade

Next Post

GameStop, Reddit, and Digital World Acquisition See Volatility Amid Market Activity

Related Posts

trading-chart-2

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

byLiliana Vida
August 4, 2025
0

AI-driven growth, strong U.S. contracts, and Trump’s cost-cutting push propel Palantir into the top 10 U.S. tech companies by market...

trading-chart-2

Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

byLuca Blaumann
July 30, 2025
0

Record Automotive Revenue and $3.8 Billion Returned to Shareholders Highlight Robust Quarter Qualcomm (QCOM) delivered solid third-quarter fiscal 2025 results,...

Palo Alto Networks Eyes $20B Deal for CyberArk

byLuca Blaumann
July 29, 2025
0

Potential Acquisition Could Reshape the Cybersecurity Landscape Palo Alto Networks (PANW) is reportedly in advanced discussions to acquire CyberArk Software...

Next Post
trading-chart

GameStop, Reddit, and Digital World Acquisition See Volatility Amid Market Activity

Latest News

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk

Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million

Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

Palo Alto Networks Eyes $20B Deal for CyberArk

Based on Your Interest

trading-chart
Ecommerece

AMD and Amazon: Two Titans Poised for Explosive Growth

July 28, 2025
Entertainment

FCC Approves $8B Paramount-Skydance Merger Amid Political Controversy

July 25, 2025
airplane
Aerospace & Defense

FAA Keeps Boeing 737 MAX Production Cap in Place Amid Ongoing Oversight

July 24, 2025

Recommended

Large-Cap

Intel Beats on Revenue, Misses on Earnings; Cuts Workforce by 15%

July 24, 2025
Brokerages

Accelerant Soars in NYSE Debut, Valued at $6.4 Billion

July 24, 2025
Distributor

GoPro and Krispy Kreme Surge as Meme Stock Frenzy Reignites

July 23, 2025
Electrical Equipment

GE Vernova Soars to Record High on Raised Cash Flow Outlook

July 23, 2025
Auto Manufacturers

Earnings Season Surprises: Coca-Cola Delivers, GM Struggles Under Tariff Pressure

July 22, 2025
Stoxpo

Follow us on social media:

Highlights

  • Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom
  • Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk
  • Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million
  • Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth
  • Palo Alto Networks Eyes $20B Deal for CyberArk

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

trading-chart-2

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

August 4, 2025
tesla

Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk

August 4, 2025
evtol

Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million

August 4, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?